SEA-CD70
- Generic Name
- SEA-CD70
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).
- Associated Conditions
- -
- Associated Therapies
- -
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04227847
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UCLA Department of Medicine - Hematology & Oncology, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath